Law360, New York (May 10, 2012, 9:35 PM ET) -- A New York federal judge on Thursday said he will likely grant class certification to a group of investors who claim Pfizer Inc. unit Wyeth Pharmaceuticals Inc. did not disclose serious side effects associated with the antidepressant Pristiq.
Investors led by a pipe fitters union have asked to go forward as a class in a suit claiming Wyeth, then an independent company, committed securities fraud by failing to disclose heart- and liver-related side effects that appeared during Pristiq's clinical trials.
“I'm going to reserve [judgment] but...
Wyeth Investors Likely To Win Class Cert. In Pristiq Case
To view the full article, take a free trial now.
